Advanced Search

Study Preview



Study Title and Description

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.



Key Questions Addressed
7 Key Question 7. What is the effectiveness of currently recommended antiviral treatments in achieving a SVR in patients with HCV infection?
  • Comments Comments (
    0
    ) |
8 Key Question 8. What are the harms of currently recommended antiviral treatments?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
Author Poordad F., Felizarta F., Asatryan A., Sulkowski MS., Reindollar RW., Landis CS., Gordon SC., Flamm SL., Fried MW., Bernstein DE., Lin CW., Liu R., Lovell SS., Ng TI., Kort J., Mensa FJ.
Country Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX.
Year 2017
Numbers Pubmed ID: 28128852

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Key Questions 1-9


Results & Comparisons

No Results found.